Laccetti, A. et al. Phase 1/2 Study of EPI-7386 in Combination with Enzalutamide (Enz) Compared with Enz Alone in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Preliminary Results from the Phase 1 (P1) Dose-optimization Component of the Study. Prostate Cancer Foundation (PCF) 2022 Scientific Retreat.

Read More > PCF 2022 Poster Presentation